AbbVie forecasts 2025 profit above estimates, driven by newer immunology drugs
1. AbbVie forecasts 2025 profit above estimates due to strong Skyrizi and Rinvoq sales. 2. Sales growth of new drugs compensates for Humira's declining market share.
FAQ
Why Bullish?
Strong sales projections for new immunology drugs can positively influence ABBV's stock performance, similar to past instances when new product launches mitigated declines from legacy drugs.
How important is it?
The forecast and sales growth are crucial indicators of ABBV's financial health, reflecting its ability to adapt in a competitive market.
Why Long Term?
If AbbVie maintains strong sales growth beyond 2025, it could enhance its long-term valuation, echoing the previous successes seen after new product introductions.